Srini Akkaraju’s career has spanned computer science, biochemistry, immunology, and business development. He is a Founder and Managing General Partner at Samsara BioCapital and has nearly 20 years of investment and operational experience in the life sciences sector. Prior to founding Samsara BioCapital, he served as a General Partner of Sofinnova Ventures from April 2013 to June 2016, Managing Director of New Leaf Venture Partners from January 2009 to April 2013, and Managing Director of Panorama Capital, a private equity firm that he helped found, from September 2006 to December 2008.
Before co-founding Panorama Capital, he was a Partner at J.P. Morgan Partners, and earlier in his career, he worked in Business and Corporate Development at Genentech. Dr. Akkaraju currently serves as a director of Aravive, Intercept Pharmaceuticals, Seattle Genetics, Syros Pharmaceutiacals, and Principia Biopharma. Previously, he served on the boards of aTyr Pharma, Barrier Therapeutics, Eyetech Pharmaceuticals, ZS Pharma, Synageva Biopharma Corp. and Amarin Corp. Dr. Akkaraju received an M.D. and a Ph.D. in Immunology from Stanford University and undergraduate degrees in Biochemistry and Computer Science from Rice University.